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Summary
Rabies is an economically important zoonosis. This paper describes the extent of
the economic impacts of the disease and some of the types of economic analyses
used to understand those impacts, as well as the trade-offs between efforts to
manage rabies and efforts to eliminate it. In many cases, the elimination of rabies
proves more cost-effective over time than the continual administration of postexposure prophylaxis, animal testing and animal vaccination. Economic analyses
are used to inform and drive policy decisions and focus political will, placing
economics at the heart of rabies control.
Keywords
Cost–benefit analysis – Dog vaccination – Health economics – Post-exposure prophylaxis
– Rabies – Zoonosis.

Introduction
Rabies is an economically unique zoonosis because most
of its associated costs do not result from illness, but are
the consequence of human deaths and efforts to prevent
the disease in humans, livestock, wildlife and companion
animals. This unique pattern of costs reflects two basic
facts: the case fatality rate of rabies in humans is nearly
100%, and the disease is completely preventable through
timely post-exposure prophylaxis (PEP) with rabies vaccine
(1). As a result, many individuals who are at very low risk of
developing the disease still seek post-exposure vaccination,
even though this may not be the recommendation of health
professionals (2).
Like all zoonotic diseases, rabies is maintained in an animal
reservoir. Each rabies virus (RABV) variant has a unique
geographical range and ecology, requiring different control
and intervention strategies. In developed countries, where
canine rabies has been eliminated, the virus may continue
to circulate in wildlife, whereas in most developing
countries, the principal reservoir is domestic dogs (Canis
lupus familiaris). Human and livestock exposure is based
on a multitude of risk factors (3, 4), and there are several

doi: 10.20506/rst.37.2.2833

pathways by which rabies causes economic damage.
Although the close relationship between humans and dogs
is the primary cause of RABV exposures for all variants,
that relationship also provides many opportunities for
mitigating its impact.
Rabies exposures in humans, companion animals or
livestock result in economic impacts associated with
vaccination or death. Because rabies patients die quickly, and
there is no effective therapy, the cost of illness is relatively
small, especially in the developing world. In contrast, the
direct costs arising from factors such as PEP and livestock
deaths are substantial, and they have been characterised in
numerous studies (3, 5, 6, 7). Rabies also has indirect costs,
including vaccination of livestock and companion animals
and testing of animals suspected of rabies (4, 8). Other
impacts of rabies on the broader economy can be captured
by examining changes in different sectors that result from
the direct and indirect impacts of the disease (9).
Of all the variants, canine RABV has been studied the most
extensively. The global economic impact of canine rabies
has been estimated by several studies and results highlight
the fact that Asia disproportionately bears the burden of
This document is a U.S. government work and
is not subject to copyright in the United States.
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this zoonosis as a result of high levels of human deaths,
high rates of PEP and low investment in preventative dog
vaccination efforts. The total cost of canine rabies has been
estimated to range from US$ 530 million in Latin America,
Asia and Africa (10) to US$ 695 million in Asia and Africa
(11). Hampson et al. (12) take into account the cost of
human life lost by calculating disability-adjusted life years
(DALYs) and estimate the overall global cost of canine rabies
at US$ 8.6 billion. Anderson & Shwiff (13) account for
the value of human life using a different methodology and
arrive at an estimated global economic burden of canine
rabies of US$ 124.2 billion annually. As a neglected disease,
rabies disproportionately affects people in poor, rural areas,
especially children (11, 14). These studies only consider
costs incurred due to canine rabies and exclude costs arising
from other RABV variants, implying that the real total cost
of rabies presence worldwide is substantially higher.
Rabies is a preventable disease in that vaccination exists for
humans, companion animals, livestock and wildlife, and a
number of countries have succeeded in eliminating canine
rabies, resulting in long-term cost savings (15, 16, 17). For
example, canine rabies was eliminated from the United
States of America (USA), through the coordinated efforts of
state and federal agencies. One of the factors in the success
of elimination efforts was the implementation of an oral
rabies vaccination (ORV) programme in wild and domestic
canids in Texas, the impact of which has been evaluated by
Shwiff et al. (16). Economic analyses such as this help to
capture the impact of rabies to society. They inform resource
allocation and disease management decisions. Understanding
the economic trade-offs between suppression and treatment
of rabies in humans versus treatment in animals is crucial to
focusing political will to address the impacts caused by the
disease. The tools exist to eliminate the disease; however, the
economics determine whether or not elimination is feasible.
This reality emphasises the importance of understanding
the benefits and costs associated with rabies management
in all potential reservoirs. This paper will describe the types
of economic analyses used in rabies research, and discuss
the status of economic research regarding rabies, which
includes human treatment, control efforts in wildlife and
potential strategies for eliminating rabies.

Types of economic analyses
A variety of types of analyses is available to economists.
Benefit–cost analyses (BCAs) or cost–benefit analyses
(CBAs) are useful for measuring and comparing the
economic efficiency of policy options. For example,
Anderson et al. (8) conducted a BCA to compare two
options for controlling vampire bat rabies in Mexico,
and Elser et al. (18) conducted a retrospective BCA on a
raccoon rabies elimination programme in New York State,
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USA. A general BCA decision framework for mitigation of
disease spread at the wildlife–livestock interface has also
been developed to identify, assemble, and measure the
components vital to the biological and economic efficiencies
of animal disease mitigation efforts (19). Cost-effectiveness
analysis is used to measure an outcome per unit of effort
(which does not have to be monetary). Wera et al. (20) used
this technique to determine the cost-effectiveness of mass
dog vaccination campaigns on Flores Island, Indonesia,
defining cost-effectiveness as public cost per averted canine
rabies case. These tools, and others, allow researchers to
determine optimal rabies management choices and provide
methodology to reveal the magnitude of the economic
impact of rabies on society.
Common metrics to measure the impact of rabies include:
the direct and indirect impacts from medical treatment
for dog bites; direct and indirect treatment for PEP; dog
vaccination efforts; livestock losses; and DALYs. Typical
results provided by economic analyses of rabies impacts
include the overall impact of the disease burden, cost per
dog vaccinated, cost per human life saved, cost of PEP,
cost of dog vaccination programmes, and DALYs. In most
cases, costs associated with human PEP make up the largest
component of costs. Unfortunately, most studies do not
have sufficient data to make these studies replicable in other
locations, which makes the results regionally specific.
A new class of models is being developed that strikes a
balance between biological sophistication and the ability
to identify optimal rabies management strategies while
recognising management resource constraints. These
models are individual-based stochastic simulations that
explicitly account for the links between effort, cost, and
biological outcomes. Additionally, the objectives of these
models are to construct a framework that i) accounts for
population and disease dynamics; ii) allows removal,
permanent sterilisation, temporary contraception and
vaccination; iii) allows strategies to vary temporally,
spatially and demographically; iv) allows mixed strategies;
v) accommodates various levels of data availability; and vi)
is flexible enough to allow parameterisation and functional
forms for a variety of wildlife species and diseases. In
the future, these models may provide a way to more
appropriately integrate biological realities and economic
considerations to provide rabies managers with the power
and flexibility to clearly highlight the benefits and costs of
different elimination strategies.

Human rabies treatment
Human rabies treatment is expensive and comprises a
significant portion of the overall economic impact of
rabies. Treatment usually consists of a series of four to five
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vaccinations over a span of several weeks, accompanied
by a dose of rabies immunoglobulin (RIG). In the USA,
medical costs for each suspected human rabies exposure,
including PEP, are estimated to total US$ 3,000 (adjusted
to 2017) and account for 70% of the cost of each rabies
exposure event (5). In developing countries of Asia and
Africa, PEP costs range from US$ 40 to US$ 64 (11, 21).
However, many people seeking PEP are unable to receive
the full course of treatment, so these costs reflect only
partial treatment. Human or equine RIG is not available in
many of these areas. In the Philippines and Tanzania, only
about 1% of patients received RIG, while just 9% received
RIG in South Africa (21). The cost of PEP is out of reach for
many people in developing countries, where daily wages
are often only US$ 1 or US$ 2 (22).

Rabies by variant
In terms of economic analysis, canine rabies has been the
most extensively studied RABV variant. This is likely the
case for several reasons. Firstly, humans are at greater risk of
contracting this variant because of their close relationship
with dogs (C. lupus familiaris), giving rise to related impacts
and generating interest in studying these impacts. Secondly,
even if the variant of rabies is commonly found in wildlife,
the route to human exposure is still mainly through dogs
as they interact with wildlife, thereby potentially exposing
humans. This section examines the literature of economic
analyses for each variant.

Raccoons
Raccoon (Procyon lotor) rabies is found primarily in the USA
and Canada. It is enzootic in south-eastern Canada and in
the north-eastern, mid-Atlantic and south-eastern regions
of the USA (23, 24). Oral rabies vaccination has been used
to prevent the spread of raccoon rabies westward, where
abundant susceptible raccoon populations exist (25, 26).
Between 2006 and 2010, approximately 38 million ORV
baits were distributed along the Appalachian Ridge to form
vaccination zones to strategically prevent the westward
spread of raccoon rabies. These zones prevent the spread of
the virus into other United States and Canadian territories,
and so far, there has not been a breach of the ORV barrier
(23, 27), indicating that this method of rabies management
may be effective for the confinement and prevention of
raccoon rabies and could be a component in potential
strategies for eliminating the raccoon RABV variant (26).
Assuming raccoon rabies would continue to move westward
in the absence of these zones, the ORV programme, coupled
with natural barriers (such as the Appalachian Mountains
and various river systems), proves to be economically
efficient. The cost of establishing and maintaining the

ORV zones is estimated to be between US$ 58 million and
US$ 148 million (27). The cost estimates of ORV in Ohio
between 1997 and 2000 were US$ 102,261 per km2, and the
mean baseline cost of blanket rabies prevention techniques
for the state is estimated to be US$ 397,728 per year (28).
Foroutan et al. (29) concluded that ground distribution of
ORV costs less than air distribution, and the cost of the baits
themselves accounts for 85% of total costs.
Although there are very few human deaths attributable to
the raccoon RABV variant in the USA, rabid raccoons pose
a significant threat to humans and pets, due to the species
being well adapted to life in urban and suburban areas (23).
Humans are at risk of rabies through direct exposure, and
exposure to pets that have been exposed to a rabid raccoon.
Though there may not be a large number of human fatalities
related to raccoon rabies, the presence of rabid raccoons
does increase the number of livestock and pets annually
tested for rabies, as well as the amount of PEP administered
in that area (27).
In March 2008, three cattle died in Hampshire County,
West Virginia, after being exposed to a rabid raccoon. The
remaining 85 cattle were euthanised once the dead cattle
tested positive for rabies, in order to prevent the spread
of the virus. In addition, ten people were evaluated for
possible exposure to rabies following the event, and all ten
received rabies PEP, resulting in an estimated total cost of
US$ 103,985 for this single event (30). In a separate event
in Guernsey, Ohio, another 64 calves were euthanised
following a confirmed death from raccoon rabies in the
herd, and six humans received PEP following the incident.
The total cost of this event was US$ 44,974 (30). These cases
highlight an important component of raccoon rabies: while
direct contact with a rabid raccoon may occur, it is often the
case that exposure is indirect through a raccoon interacting
with dogs and cats (Felis catus) as well as livestock, resulting
in potential human exposure.

Skunks and bats
Skunk rabies cases comprise about 26% of all wild animal
rabies cases in North America, and the three skunk RABV
variants collectively have the broadest geographical
distribution in the USA, occurring in 22 north and southcentral states and California (24). While there is no ORV bait
available for skunks or bats, several baits are in development
and research has highlighted the economic necessity for
this development (31). In California specifically, rabies
is enzootic, with striped skunks (Mephitis mephitis) and
bats (Chiroptera) acting as the main wildlife reservoirs.
Seventy percent of California rabies cases are linked to
terrestrial species that most often include striped skunks,
spotted skunks (Spilogale putorius), and grey foxes (Urocyon
cinereoargenteus), and 30% of cases involve bats (31).
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Bats also comprise approximately 26% of all reported rabies
cases in the USA, and are the second-most reported rabid
animal (24). Since 2000, vampire bats (Desmodus rotundus)
have been the leading cause of human rabies in Latin America
and the Caribbean (32), and vampire bat rabies is a major
public health concern in tropical and subtropical areas of
Latin America (8). Vampire bats transmit RABV to livestock
and humans through their haematophagous behaviour, and
are often the species most responsible for the transmission
of RABV to livestock (8). In cattle, bat rabies can result in
hide damage, weight loss, decreased milk production and
death. Rabies virus transmitted to humans by bats results in
death if PEP is not administered (8).
The vampire bat can be found in Mexico as far north as
the states of Sonora and Tamaulipas, and could potentially
extend into south Texas in the next few decades as a result
of climate change (33). Between 1997 and 2006, the
average annual number of PEP treatments administered in
Mexico was 955, costing 1,500 Mexican pesos (US$ 77) per
person (8). If vampire bat rabies were to spread to southern
Texas, the total economic impact is estimated to be between
US$ 7 million and US$ 9.2 million (33). Vaccination of bat
populations through ORV and available vaccine strategies
is not feasible (8). Primary means of vampire bat rabies
mitigation are bat control and livestock vaccination.
Livestock vaccination has been found to be economically
efficient while bat control has not (8).

Dogs
Rabies in canids causes the greatest economic impact of all
the variants, in that 99% of all global human rabies cases
are caused by domestic dogs (24). As a result, the canine
variant has received the most research attention and most
published evidence about the impact of rabies is about
this variant. However, there is still a substantial lack of
information regarding the overall economic impact of
canine rabies and the value of dog vaccination programmes,
as well as a lack of data that can be extrapolated to other
canine rabies-endemic regions (25, 34). A few studies
provide overall estimates of the global impact of canine
rabies; however, the majority of the studies that address the
economics of canine rabies deal with a specific region or
dog vaccination programme evaluation and are unsuited for
replication in other regions.
An estimated 7.5 million people receive PEP each year
as a result of potential exposure to canine RABV, and the
total cost of canine rabies has been estimated to range from
US$ 530 million to US$ 124 billion, depending on the
regions being considered and the cost components included
(10, 11, 12, 13). The cost for an individual PEP treatment
ranges between US$ 30 and US$ 40 across all regions (10),
and it has been estimated that 83% of the total rabies control
budget in both Asia and Africa is put towards PEP (35).
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Canine rabies causes an estimated 59,000 human deaths
per year, although estimates can go as high as 69,000, and is
responsible for the loss of 3.7 million DALYs annually (10,
12). The majority of those deaths occur in Africa (36.4%)
and Asia (59.6%), with only 0.05% of deaths occurring in
the Americas, 70% of which occur in Haiti (12). India alone
accounts for 35% of human deaths from canine rabies, but
the estimated death rate was highest in the poorest countries
in sub-Saharan Africa (12). The role of rabies prevention
can be clearly seen when we look at the figures for PEP and
dog vaccination in the different regions: for each human
death attributed to canine rabies, Latin America performs
41,000 PEP treatments and vaccinates 2.8 million dogs,
Asia performs 200 PEP treatments and about 1,000 dog
vaccinations, and Africa performs eight PEP treatments and
vaccinates eight dogs (10).
Several dog vaccination campaigns have been undertaken to
address endemic canine rabies in developing countries. The
World Health Organization (WHO), with funding support
from the Bill and Melinda Gates Foundation, addressed
canine rabies in three sites: South-eastern Tanzania; Cebu
Province in the Philippines; and KwaZulu-Natal Province
in South Africa (21). A study of the economic costs of
these projects found that the cost per dog vaccinated
varied (range: US$ 1.18 to US$ 6.61) and appeared to be
influenced by human and dog density (costs were lower
where densities were higher), as well as overall vaccination
coverage. Transportation costs were insignificant in urban
areas but they were an important cost driver in rural areas,
where house-to-house campaigns were required to reach
dispersed populations. The vaccine itself accounted for a
very small portion of the total cost of dog vaccination. In
contrast, the cost of the average human PEP course ranged
from US$ 44.91 to US$ 64.38 across the three sites. It is
important to note that many bite victims did not receive
the full course of treatment, and very few received RIG
(range: 1% to 9%). Others did not seek treatment at all,
so the PEP costs reported here were lower than would be
required if every bite victim received a complete course
of PEP. This study demonstrated that the cost and success
of a dog vaccination campaign will be highly site specific,
varying according to the presence or absence of an existing
rabies management programme, knowledge of the local dog
population, and support from external donors. Léchenne
et al. (36) reported that a mass dog vaccination campaign
in N’Djamena, Chad, achieved more than 70% coverage
and resulted in a 90% decrease in reported dog rabies
cases within one year, illustrating the profound impact dog
vaccination programmes can have on rabies prevalence.
Haiti remains one of the few rabies-endemic countries in
the Western Hemisphere. It is estimated that only 31%
of people exposed to rabies seek treatment, resulting in
130 deaths each year (37). A survey conducted in Haiti
revealed that 3.2% of respondents had experienced a dog
bite in the previous year, which is problematic in a country
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where the dog vaccination rate does not reach the 70%
threshold recommended for herd immunity (38). Haiti
represents a country where increased dog vaccination could
significantly reduce the prevalence of rabies, but further
knowledge of dog ecology and increased access to vaccines
are necessary.
In 1987, a canine rabies outbreak took place in Hermosillo,
Mexico, resulting in 2.5% of city residents being bitten by
a dog, 60% of whom were administered PEP. The PEP cost
of this single outbreak was an estimated US$ 682,500 per
100,000 citizens (39). In 1988 in the USA, an epizootic
of canine rabies began in South Texas. It continued for
six years, during which time 216 domestic dogs and
270 coyotes (Canis latrans) were confirmed rabid. Over
these six years, aerial baiting was used to dispense vaccineladen baits throughout the infected area, costing a total of
over US$ 26 million (16). The integration of ORV was a
major contributing factor that led to freeing the USA of
canine rabies (26). Mass dog vaccination campaigns in
Tanzania and Bali Island, Indonesia, have been successful
in decreasing cases of rabies in dogs and humans (35).
Flores Island, Indonesia, is populated by more than
1.8 million humans and 236,500 dogs, and there have
been 19 reported cases of human fatalities attributed to
canine rabies (35). Between 2001 and 2011, the average
annual cost of rabies and rabies control on Flores Island
was approximately US$ 1.12 million. Costs associated
with rabies and rabies control on Flores Island included
the culling of dogs, PEP administration, mass vaccination,
pre-exposure treatment, dog bite investigation, testing
of dogs suspected of being rabid, and the quarantine of
imported dogs (35). Of those costs, dog culling is the most
expensive, accounting for 39% of the total cost, followed
by PEP treatments (35%) and mass vaccination of canines
(24%). The total cost of rabies control measures in humans
on Flores Island is estimated to be US$ 4.82 million. In
Indonesia, 150 to 300 fatal rabies cases in humans are
reported annually (35).
In most cultures, dogs provide companionship and
are woven into the social fabric of everyday life, which
provides the pathway to impacts but also the means by
which elimination is possible. Vaccination of dogs is the
key to prevention and elimination of RABV in dogs and
humans, while PEP only prevents rabies in humans but
does not have any potential to eliminate the disease (40).
In addition, in developing countries, PEP is relatively
expensive (costs may exceed two to three months of wages)
and often difficult to obtain (3, 41, 42). Bögel and Meslin
(40) determined that, after 15 years, a canine rabies control
programme consisting of a combination of PEP and canine
vaccination becomes more cost effective than PEP alone.
In one African city, the costs of a combined programme of
PEP and canine rabies vaccination achieved parity with the
costs of PEP alone after six years (3). The economic analyses

of canine rabies highlighted in this paper commonly point
to several reoccurring themes, such as the fact that rabies
is preventable and elimination is possible but requires
extensive dog vaccinations that can be costly. Canine rabies
can cause substantial economic loss, but it is completely
preventable and its prevention is economically efficient.
Elimination is possible if political will generates enough
support for successful mass dog vaccination campaigns.

Conclusions
Not all losses from zoonotic diseases are preventable
(4, 43). In some cases, effective vaccines do not exist for all
of the main vectors and, in the case of highly contagious
zoonoses, large outbreaks can happen rapidly and involve
thousands of people simultaneously. In addition, for those
zoonotic diseases that have high morbidity implications,
illness can persist for a long time, causing economic impacts
for many years. Rabies, however, is unique, in that the
economic impact of the disease is not a result of morbidity
and is only associated with mortality to a limited extent;
rather, it is mainly the result of management of the disease
and treatment to prevent human death. This zoonosis is
unique in that a vaccine exists for almost all of the reservoir
species and certainly the most important, namely dogs, and
this means elimination is feasible. The result of all of these
factors is that economic gains can be made by the successful
elimination of the disease.
A consistent finding across most studies of the economic
impact of rabies is that vaccinating reservoir species is key
to reducing impacts. In terms of canine rabies, the evidence
is clear and consistent: vaccination of dogs reduces human
impacts in terms of human death and causes a decrease in
the number of PEP treatments carried out. Those countries
or regions most impacted by rabies are those that choose
to invest less in dog vaccination efforts and more in PEP.
This is best exemplified by Asia, which experiences over
half of all human and cattle deaths while performing
more than 90% of PEP vaccinations and about half of dog
vaccine administrations. Asia invests the least in PEP and
dog vaccination per human death. Latin America invests
heavily in human death prevention in that, for every human
death, it has administered over 40,000 PEP treatments and
vaccinated 2.8 million dogs. Asia, however, only performs
eight PEP treatments and eight dog vaccinations per human
death. This conclusively determines why there is minimal
loss of human life in Latin America due to rabies and
substantial loss of life to rabies in Asia.
Enough economic analysis has been conducted globally to
prove that canine rabies elimination can be economically
efficient and provide a positive return on investment.
Future economic analysis will likely be able to illustrate the
trade-offs between different management goals and budget
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constraints. Managers will be able to clearly illustrate the
value of mass dog vaccination campaigns in reducing the
need for PEP and saving human lives. Ultimately, this

should generate the political support needed to meet the
goal of eliminating canine rabies worldwide by 2030.

Analyse du rapport coûts-bénéfices de la lutte contre la rage :
placer l’économie au cœur de la lutte contre la rage pour mobiliser
la volonté politique
S.A. Shwiff, J.L. Elser, K.H. Ernst, S.S. Shwiff & A.M. Anderson
Résumé
La rage est une zoonose importante au plan économique. Les auteurs décrivent
la portée de l’impact économique de la rage et présentent quelques modèles
d’analyse économique utilisés pour comprendre ces effets ; ils analysent
également les compromis à trouver entre les efforts consacrés à la gestion de
la rage et ceux dédiés à son élimination. Dans bien des cas, il est plus rentable
sur le long terme d’éliminer la rage que de procéder à la gestion continue de
la prophylaxie post-exposition chez l’homme et au dépistage et à la vaccination
des animaux. Les analyses économiques servent à documenter et à orienter les
décisions concernant les mesures à prendre afin de mobiliser la volonté politique
nécessaire, en plaçant l’économie au cœur de la lutte contre la rage.
Mots-clés
Analyse du rapport coûts-bénéfices – Économie de la santé – Prophylaxie post-exposition
– Rage – Vaccination des chiens – Zoonose.

Análisis de la relación costo-beneficio del control de la rabia,
o cómo hacer de la economía el eje de la lucha antirrábica para
aglutinar la voluntad política
S.A. Shwiff, J.L. Elser, K.H. Ernst, S.S. Shwiff & A.M. Anderson
Resumen
La rabia es una zoonosis que reviste importancia económica. Los autores
exponen la magnitud del impacto económico de la enfermedad y algunas
de las modalidades de análisis económico utilizadas para aprehender esas
consecuencias, así como el juego de equilibrios entre las medidas de gestión de
la rabia y las actividades destinadas a eliminarla. En muchos casos, la eliminación
de la enfermedad ofrece a la larga mayor eficacia, en relación con el costo, que
la continua labor de administración de profilaxis tras exposición, realización de
pruebas en animales y vacunación de estos. Los análisis económicos sirven
para fundamentar y encauzar las decisiones de planificación y para aglutinar la
voluntad política, haciendo de los aspectos económicos un eje de la lucha contra
la rabia.
Palabras clave
Análisis de la relación costo-beneficio – Economía de la salud – Profilaxis tras exposición
– Rabia – Vacunación canina – Zoonosis.
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